EUCTR2011-003732-31-NL进行中（未招募）不适用
A randomized, double-blind, parallel-group, 26-week study comparing the efficacy and safety of indacaterol (Onbrez® Breezhaler® 150 µg o.d.) with salmeterol/fluticasone propionate (Seretide® Accuhaler® 50 µg/500 µg b.i.d.) in patients with moderate chronic obstructive pulmonary disease.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with moderate COPD (Stage II)
- •- Able to perform spirometry assessments
- •- Current or ex-smokers
- •- On treatment with the fixed-dose combination of salmeterol 50 µg /fluticasone propionate 500 µg MDDPI b.i.d. for the treatment of COPD for =3 months directly
- •Other protocol-defined inclusion/exclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 450
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •- Having had a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the past year.
- •- A history of, or current ECG abnormality.
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
不适用
To compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are being treated with salmeterol /fluticasone propionateChronic obstructive pulmonary diseaseMedDRA version: 14.1Level: SOCClassification code 10038738Term: Respiratory, thoracic and mediastinal disordersSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-003732-31-ITOVARTIS FARMA600
进行中（未招募）
1 期
To compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are being treated with salmeterol /fluticasone propionate.Chronic obstructive pulmonary diseaseMedDRA version: 14.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-003732-31-GBovartis Pharma Services AG581
进行中（未招募）
不适用
To compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are being treated with salmeterol /fluticasone propionate.Chronic obstructive pulmonary diseaseMedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-003732-31-ESovartis Farmacéutica SA600
进行中（未招募）
1 期
A study of the efficacy and safety of NVA237 in patients with moderate to severe COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 18.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-004818-28-PLovartis Pharma Services AG752
进行中（未招募）
1 期
A study of the efficacy and safety of NVA237 in patients with moderate to severe COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 18.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-004818-28-BGovartis Pharma Services AG752